LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。本研究的目的是确定当Abraxane每周一次或每3周一次给药时，可以与卡铂一起安全给予的Abraxane的最高剂量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine highest dose of Abraxane that can be safely given with carboplatin when Abraxane is given once a week or every 3 weeks.